This observational, multi-center study will evaluate the treatment regimen, treatment responses and safety of RoActemra/Actemra (tocilizumab) therapy in a routine clinical practice in patients with moderate to severe rheumatoid arthritis. Data will be collected for 6 months.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01664104?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
